Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Nagasaka · SciRah

Researcher profile · Semantic Scholar

M. Nagasaka

Share profile

M. Nagasaka — researcher profile on SciRah

h-index: 39
Works: 236
Citations: 6,073

Most-cited papers

Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial
J. Chaft, F. Oezkan, M. Kris, P. Bunn +32 more
2022Nature Medicine233 citations Open access
Semantic Scholar
Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors
Jessica K. Lee, S. Sivakumar, A. Schrock, R. Madison +14 more
2022npj Precision Oncology173 citations Open access
Semantic Scholar
Trastuzumab Deruxtecan-Induced Interstitial Lung Disease/Pneumonitis in ERBB2-Positive Advanced Solid Malignancies: A Systematic Review
Z. Abuhelwa, A. Alloghbi, Ali J Alqahtani, M. Nagasaka
2022Drugs114 citations Open access
Semantic Scholar
Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial
B. Cho, Dong-Wan Kim, A. Spira, Jorge E. Gomez +20 more
2023Nature Medicine103 citations Open access
Semantic Scholar
NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability
Hui Wang, Zhi-wei Li, Q. Ou, Xue Wu +4 more
2022Cancer Medicine59 citations Open access
Semantic Scholar
Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers.
A. Schram, K. Goto, Dong-Wan Kim, P. Martin-Romano +16 more
2022Journal of Clinical Oncology58 citations
Semantic Scholar
Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial
V. Boni, M. Fidler, H. Arkenau, A. Spira +24 more
2022Clinical Cancer Research58 citations Open access
Semantic Scholar
A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC)
Z. Abuhelwa, A. Alloghbi, M. Nagasaka
2022Cancer Treatment Reviews58 citations Open access
Semantic Scholar
Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges
Khalil Choucair, Hafsa Imtiaz, M. H. Uddin, M. Nagasaka +5 more
2025Signal Transduction and Targeted Therapy56 citations Open access
Semantic Scholar
Low dose computed tomography (LDCT) screening in Asian female never-smokers is as efficacious in detecting lung cancer as in Asian male-ever-smokers: a systematic review and meta-analysis.
N. Triphuridet, Shannon S. Zhang, M. Nagasaka, Yan-Fei Gao +5 more
2023Journal of Thoracic Oncology51 citations Open access
Semantic Scholar
NRG1 and NRG2 fusion positive solid tumor malignancies: a paradigm of ligand-fusion oncogenesis.
M. Nagasaka, S. Ou
2022Trends in Cancer50 citations Open access
Semantic Scholar
Neoadjuvant EGFR-TKI therapy in Non-Small cell lung cancer.
C. Grant, M. Nagasaka
2024Cancer Treatment Reviews48 citations Open access
Semantic Scholar
Neoadjuvant Therapy in Non-Small Cell Lung Cancer.
C. Grant, G. Hagopian, M. Nagasaka
2023Critical reviews in oncology/hematology35 citations Open access
Semantic Scholar
TRUST-II: a global phase II study of taletrectinib in ROS1-positive non-small-cell lung cancer and other solid tumors.
M. Nagasaka, Y. Ohe, Cai-Cun Zhou, Chang-Min Choi +17 more
2023Future Oncology33 citations Open access
Semantic Scholar
Abstract CT028: A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors
Y. Murciano-Goroff, R. Heist, Y. Kuboki, T. Koyama +21 more
2023Cancer Research31 citations
Semantic Scholar
Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options
Danielle Brazel, G. Kroening, M. Nagasaka
2022BioDrugs31 citations Open access
Semantic Scholar
Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non–small cell lung cancer
V. Rusch, A. Nicholas, G. Patterson, Salama N. Waqar +25 more
2022Journal of Thoracic and Cardiovascular Surgery30 citations Open access
Semantic Scholar
BLU-945 monotherapy and in combination with osimertinib (OSI) in previously treated patients with advanced EGFR-mutant (EGFRm) NSCLC in the phase 1/2 SYMPHONY study.
Y. Elamin, M. Nagasaka, E. Shum, L. Bazhenova +16 more
2023Journal of Clinical Oncology29 citations
Semantic Scholar
Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno
Danielle Brazel, S. Ou, M. Nagasaka
2023Lung Cancer28 citations Open access
Semantic Scholar
Efficacy of Corticosteroid Therapy for HTLV-1-Associated Myelopathy: A Randomized Controlled Trial (HAMLET-P)
J. Yamauchi, Kenichiro Tanabe, Tomoo Sato, M. Nakagawa +23 more
2022Viruses28 citations Open access
Semantic Scholar
Characterization of MET Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome Sequencing
So Yeon Kim, Jun Yin, S. Bohlman, P. Walker +14 more
2022JTO Clinical and Research Reports28 citations Open access
Semantic Scholar
Connecting the Human Microbiome and Pancreatic Cancer
R. Sexton, M. H. Uddin, S. Bannoura, H. Khan +9 more
2022Cancer Metastasis Review28 citations Open access
Semantic Scholar
Comprehensive review of ROS1 tyrosine kinase inhibitors (TKIs)-classified by structural designs and mutation spectrum [solvent front mutation (G2032R) and central β-sheet 6 (Cβ6) mutation (L2086F)].
S. Ou, G. Hagopian, Shannon S. Zhang, M. Nagasaka
2023Journal of Thoracic Oncology26 citations Open access
Semantic Scholar
Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset
M. Nagasaka, D. Brazel, Y. Baca, J. Xiu +10 more
2023Translational Oncology24 citations Open access
Semantic Scholar
Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C–Mutant Cancers
H. Khan, M. Nagasaka, Yi-Wei Li, A. Aboukameel +14 more
2022bioRxiv24 citations Open access
Semantic Scholar
Oncogenic Fusions: Targeting NTRK.
G. Hagopian, M. Nagasaka
2023Critical reviews in oncology/hematology23 citations Open access
Semantic Scholar
The Development and Role of Capmatinib in the Treatment of MET-Dysregulated Non-Small Cell Lung Cancer—A Narrative Review
R. Hsu, David J. Benjamin, M. Nagasaka
2023Cancers21 citations Open access
Semantic Scholar
Amivantamab (JNJ-61186372) induces clinical, biochemical, molecular, and radiographic response in a treatment-refractory NSCLC patient harboring amplified triple EGFR mutations (L858R/ T790M/G796S) in cis.
M. Nagasaka, A. Balmanoukian, R. Madison, Shannon S. Zhang +2 more
2022Lung Cancer18 citations Open access
Semantic Scholar
Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation
Danielle Brazel, Shannon S. Zhang, M. Nagasaka
2022Lung Cancer18 citations Open access
Semantic Scholar
The development of amivantamab for the treatment of non-small cell lung cancer
Danielle Brazel, M. Nagasaka
2023Respiratory Research16 citations Open access
Semantic Scholar
Overview of Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Targeted Therapy and Supportive Care for Lung Cancer
Kaleem Anwar, Lee Nguyen, M. Nagasaka, S. Ou +1 more
2022JTO Clinical and Research Reports16 citations Open access
Semantic Scholar
CheckMate-722: The Rise and Fall of Nivolumab with Chemotherapy in TKI-Refractory EGFR-Mutant NSCLC
Alexandria T M Lee, M. Nagasaka
2023Lung Cancer15 citations Open access
Semantic Scholar
Phase 2 trial of adjuvant nivolumab following salvage resection in patients with recurrent squamous cell carcinoma of the head and neck
J. Leddon, S. Gulati, S. Haque, C. Allen +17 more
2022Clinical Cancer Research15 citations Open access
Semantic Scholar
Severity of Financial Toxicity for Patients Receiving Palliative Radiation Therapy
J. Harris, E. Ku, G. Harada, S. Hsu +6 more
2023The American journal of hospice & palliative care14 citations Open access
Semantic Scholar
From preclinical efficacy to 2022 updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced ALK+ NSCLC.
S. Ou, Alexandria T M Lee, M. Nagasaka
2023Critical reviews in oncology/hematology14 citations Open access
Semantic Scholar
MARIPOSA: Can Amivantamab and Lazertinib Replace Osimertinib in the Front-Line Setting?
Danielle Brazel, M. Nagasaka
2024Lung Cancer13 citations Open access
Semantic Scholar
Proteolysis targeting chimeras in non-small cell lung cancer.
G. Hagopian, C. Grant, M. Nagasaka
2023Cancer Treatment Reviews13 citations Open access
Semantic Scholar
Pan-tumor survey of ROS1 fusions detected by next-generation RNA and whole transcriptome sequencing
M. Nagasaka, Shannon S. Zhang, Y. Baca, J. Xiu +8 more
2023BMC Cancer13 citations Open access
Semantic Scholar
A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib
Danielle Brazel, Z. Arter, M. Nagasaka
2022Lung Cancer12 citations Open access
Semantic Scholar
Spotlight on Cemiplimab-rwlc in the Treatment of Non-Small Cell Lung Cancer (NSCLC): Focus on Patient Selection and Considerations
Jeff Ahn, M. Nagasaka
2023Cancer Management and Research11 citations Open access
Semantic Scholar
Consolidative Radiotherapy in Oligometastatic and Oligoprogressive NSCLC: A Systematic Review.
Nazmul Hasan, O. Yazdanpanah, Jeremy P. Harris, M. Nagasaka
2025Critical reviews in oncology/hematology10 citations Open access
Semantic Scholar
Pivotal topline data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+ advanced non-small cell lung cancer (NSCLC)
B. Cho, J. Lin, D. Camidge, V. Velcheti +16 more
2022European Journal of Cancer10 citations Open access
Semantic Scholar
CodeBreak 200: Sotorasib Has Not Broken the KRASG12C Enigma Code
Shannon S. Zhang, Alexandria Lee, M. Nagasaka
2023Lung Cancer9 citations Open access
Semantic Scholar
Risk factors for venous thromboembolism (VTE) among patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) receiving amivantamab plus lazertinib versus either agent alone.
N. Girard, B. Cho, A. Spira, C. Shu +16 more
2023Journal of Clinical Oncology9 citations Open access
Semantic Scholar
Spotlight on Patritumab Deruxtecan (HER3-DXd) from HERTHENA Lung01. Is a Median PFS of 5.5 Months Enough in Light of FLAURA-2 and MARIPOSA?
Z. Arter, M. Nagasaka
2024Lung Cancer8 citations Open access
Semantic Scholar
NRG1 fusions in solid tumors.
Brinda Gupta, Sharon Wu, S. Ou, S. Darabi +11 more
2023Journal of Clinical Oncology8 citations
Semantic Scholar
Controversies in Lung Cancer: Heterogeneity in Treatment Recommendations for Stage III NSCLC According to Disease Burden and Oncogenic Driver Alterations.
J. Harris, D. Fujimoto, M. Nagasaka, E. Ku +8 more
2022Clinical Lung Cancer8 citations Open access
Semantic Scholar
Multiomic Characterization and Molecular Profiling of Nuclear Protein in Testis Carcinoma
G. Kroening, Jia Luo, Mark G. Evans, T. Adeyelu +13 more
2024JCO Precision Oncology7 citations Open access
Semantic Scholar
Adagrasib in KRYSTAL-12 has Not Broken the KRAS G12C Enigma Code of the Unspoken 6-Month PFS Barrier in NSCLC
Alexandria T M Lee, M. Nagasaka
2024Lung Cancer7 citations Open access
Semantic Scholar
First results from the RETgistry: A global consortium for the study of resistance to RET inhibition in RET-altered solid tumors.
Alissa J Cooper, A. Drilon, J. Rotow, Stephen V. Liu +16 more
2023Journal of Clinical Oncology7 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

S. Ou×9
Invite
S. Ou — researcher profile on SciRah
Shannon S. Zhang×6
Invite
Shannon S. Zhang — researcher profile on SciRah
Danielle Brazel×6
Invite
Danielle Brazel — researcher profile on SciRah
S. Ou×4
Invite
S. Ou — researcher profile on SciRah

×4

Invite

A. Spira — researcher profile on SciRah

Invite

A. Azmi — researcher profile on SciRah

Invite

G. Hagopian — researcher profile on SciRah

Invite

E. Haura — researcher profile on SciRah

Invite

E. Shum — researcher profile on SciRah

Invite

D. Camidge — researcher profile on SciRah

Invite

B. Cho — researcher profile on SciRah

Invite

R. Sanborn — researcher profile on SciRah